ACA
GSK icon

Atlas Capital Advisors’s GSK GSK Stock Holding History

Atlas Capital Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Sell
4,235
-840
-17% -$44.4K 0.02% 443
2026
Q1 		$280K Buy
5,075
+740
+17% +$40.1K 0.03% 360
2025
Q4 		$213K Buy
+4,335
New +$202K 0.02% 406
2025
Q2 		– Sell
-465
Closed -$18K – 964
2025
Q1 		$18K Buy
+465
New +$17K ﹤0.01% 746
2024
Q4 		– Sell
-5,758
Closed -$235K – 954
2024
Q3 		$235K Buy
5,758
+608
+12% +$24.9K 0.04% 351
2024
Q2 		$198K Sell
5,150
-608
-11% -$25.6K 0.03% 382
2024
Q1 		$247K Buy
5,758
+68
+1% +$2.8K 0.04% 334
2023
Q4 		$211K Buy
5,690
+4,904
+624% +$176K 0.03% 362
2023
Q3 		$28.5K Hold
786
– – ﹤0.01% 604
2023
Q2 		$28K Sell
786
-493
-39% -$17.7K ﹤0.01% 641
2023
Q1 		$45.5K Hold
1,279
– – 0.01% 578
2022
Q4 		$44.9K Hold
1,279
– – 0.01% 555
2022
Q3 		$37.6K Sell
1,279
-10,822
-89% -$410K 0.01% 572
2022
Q2 		$658K Sell
12,101
-63
-0.5% -$3.48K 0.11% 153
2022
Q1 		$662K Buy
12,164
+126
+1% +$6.84K 0.1% 175
2021
Q4 		$664K Buy
12,038
+11,834
+5,801% +$616K 0.1% 176
2021
Q3 		$9.74K Buy
+204
New +$10.2K ﹤0.01% 727
2021
Q1 		– Sell
-1,373
Closed -$63.1K – 806
2020
Q4 		$63.1K Buy
+1,373
New +$63.1K 0.01% 449
2020
Q2 		– Sell
-138
Closed -$6.55K – 700
2020
Q1 		$6.55K Buy
+138
New +$7.36K ﹤0.01% 602
2019
Q3 		– Sell
-15,825
Closed -$792K – 664
2019
Q2 		$792K Buy
15,825
+11,629
+277% +$584K 0.26% 106
2019
Q1 		$219K Hold
4,196
– – 0.08% 251
2018
Q4 		$200K Buy
+4,196
New +$207K 0.08% 255

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Atlas Capital Advisors's GSK Position: Q2 2026 in Review

Atlas Capital Advisors reduced its GSK (GSK) stake by 17% in Q2 2026, selling an estimated $44.4K and leaving 4,235 shares worth $222K. The position accounts for 0.02% of the portfolio, ranked #443.

Atlas Capital Advisors first reported a position in GSK in Q4 2018 and has held it in 22 quarters since. The position peaked at $792K in Q2 2019. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Atlas Capital Advisors held 4,235 shares of GSK worth $222K as of Q2 2026.
  • Atlas Capital Advisors sold 840 GSK shares in Q2 2026, an estimated $44.4K.
  • GSK made up 0.02% of Atlas Capital Advisors's portfolio in Q2 2026, its #443 holding.
  • Atlas Capital Advisors first reported a position in GSK in Q4 2018 and has held it in 22 quarters since.
  • Atlas Capital Advisors's GSK position peaked at $792K in Q2 2019.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Atlas Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.